ERBB2 and cancer: The majority of claudin-low tumors (61% to 71%) fall into the clinical classification of triple-negative breast cancers [24], which lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2), and are aggressive cancers that confer poor clinical outcomes.